Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:RSPI NASDAQ:TFFP OTCMKTS:TRPXD NASDAQ:VINC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRSPICortex Pharmaceuticals$0.00+114.3%$0.00$0.00▼$0.00$1.42M0.14491,208 shs12,000 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23N/A0.981.04 million shsN/ATRPXDTherapix Biosciences$0.00$2.75▼$22.40$299KN/A1,852 shs900 shsVINCVincerx Pharma$0.05-0.9%$0.05$0.04▼$17.00$237K1.72443,560 shs65,748 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRSPICortex Pharmaceuticals0.00%+36.36%+114.29%-21.05%+50.00%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-96.64%TRPXDTherapix Biosciences0.00%0.00%0.00%0.00%0.00%VINCVincerx Pharma-0.88%-2.59%-16.30%-83.56%-99.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRSPICortex PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATRPXDTherapix BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AVINCVincerx Pharma3.1748 of 5 stars3.53.00.00.02.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRSPICortex Pharmaceuticals 0.00N/AN/AN/ATFFPTFF Pharmaceuticals 0.00N/AN/AN/ATRPXDTherapix Biosciences 0.00N/AN/AN/AVINCVincerx Pharma 3.00Buy$40.0088,395.58% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRSPICortex PharmaceuticalsN/AN/AN/AN/AN/AN/ATFFPTFF Pharmaceuticals$730K0.40N/AN/A$4.04 per share0.02TRPXDTherapix BiosciencesN/AN/AN/AN/A$0.28 per shareN/AVINCVincerx PharmaN/AN/AN/AN/A$10.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRSPICortex Pharmaceuticals-$2.10MN/A0.00∞N/AN/AN/AN/AN/ATFFPTFF Pharmaceuticals-$21.24M-$6.440.00∞N/AN/AN/AN/AN/ATRPXDTherapix Biosciences-$4.79MN/A0.00N/AN/AN/AN/AN/AN/AVINCVincerx Pharma-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%8/12/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRSPICortex PharmaceuticalsN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ATRPXDTherapix BiosciencesN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRSPICortex PharmaceuticalsN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/ATRPXDTherapix BiosciencesN/A0.49N/AVINCVincerx PharmaN/A2.172.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRSPICortex PharmaceuticalsN/ATFFPTFF Pharmaceuticals15.25%TRPXDTherapix Biosciences14.32%VINCVincerx Pharma44.02%Insider OwnershipCompanyInsider OwnershipRSPICortex Pharmaceuticals50.03%TFFPTFF Pharmaceuticals4.50%TRPXDTherapix BiosciencesN/AVINCVincerx Pharma15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRSPICortex Pharmaceuticals2949.46 million474.45 millionNot OptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionableTRPXDTherapix Biosciences850,000N/ANot OptionableVINCVincerx Pharma605.23 million1.89 millionNot OptionableRSPI, TRPXD, TFFP, and VINC HeadlinesRecent News About These CompaniesVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...July 16 at 4:42 PM | gurufocus.comVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution ProposalJuly 16 at 4:19 PM | globenewswire.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila TimesJuly 9, 2025 | manilatimes.netMVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - MorningstarJuly 9, 2025 | morningstar.comMVincerx Pharma, Inc. Common Stock (VINC) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to StockholdersJuly 7, 2025 | globenewswire.comVincerx Pharma, Inc. (VINC) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comVincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution ProposalJune 18, 2025 | globenewswire.comVincerx Pharma announces plan to delist from NasdaqApril 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | finance.yahoo.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | globenewswire.comVincerx's final merger attempt collapses, leaving ADC biotech to wind downApril 9, 2025 | fiercebiotech.comFVincerx terminates letter of intent with Global Digital, initiates wind downApril 9, 2025 | markets.businessinsider.comFinancially struggling drugmaker's potential rescue falls apart. It now will wind downApril 9, 2025 | bizjournals.comVincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down ActivitiesApril 8, 2025 | globenewswire.comVincerx Pharma announces non-binding LOI for Qumulus AI combinationMarch 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | finanznachrichten.deVincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisisMarch 18, 2025 | fiercebiotech.comFVincerx Pharma Shares Soar on Proposed Merger with Global Digital HoldingsMarch 18, 2025 | marketwatch.comVincerx Pharma, Inc. Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRSPI, TRPXD, TFFP, and VINC Company DescriptionsCortex Pharmaceuticals OTCMKTS:RSPI$0.0015 +0.00 (+114.29%) As of 07/18/2025 03:34 PM EasternRespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.TFF Pharmaceuticals NASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.Therapix Biosciences OTCMKTS:TRPXDTherapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.Vincerx Pharma NASDAQ:VINC$0.05 0.00 (-0.88%) As of 07/18/2025 02:55 PM EasternVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
